Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMVT Immunovant, Inc.

Closed 01-08 16:00:00 EST

23.63

-1.01

-4.10%

盘后23.90

+0.27+1.14%

19:04 EST

High24.65	Low23.62	Vol769.99K
Open24.60	D1 Closing24.64	Amplitude4.18%
Mkt Cap3.47B	Tradable Cap1.55B	Total Shares146.78M
T/O18.35M	T/O Rate1.17%	Tradable Shares65.66M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IMVT","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":23.63,"timestamp":1736370000000,"preClose":24.64,"halted":0,"volume":769985,"hourTrading":{"tag":"盘后","latestPrice":23.9,"preClose":23.63,"latestTime":"19:04 EST","volume":56824,"amount":1342895.37,"timestamp":1736381048896},"delay":0,"floatShares":65661965,"shares":146784639,"eps":-2.215084,"marketStatus":"Closed","change":-1.01,"latestTime":"01-08 16:00:00 EST","open":24.6,"high":24.65,"low":23.62,"amount":18354796.17207,"amplitude":0.041802,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.215084,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1736499600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":24.64,"preHourTrading":{"tag":"盘前","latestPrice":24.63,"preClose":24.64,"latestTime":"09:29 EST","volume":621,"amount":15559.55244,"timestamp":1736346599999},"postHourTrading":{"tag":"盘后","latestPrice":23.9,"preClose":23.63,"latestTime":"19:04 EST","volume":56824,"amount":1342895.37,"timestamp":1736381048896},"volumeRatio":1.191528,"impliedVol":0.4104,"impliedVolPercentile":0.2262},"requestUrl":"/m/hq/s/IMVT","defaultTab":"news","newsList":[{"id":"2500173112","title":"Immunovant Cut to Peer Perform From Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2500173112","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500173112?lang=en_us&edition=fundamental","pubTime":"2025-01-03 22:59","pubTimestamp":1735916340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 03, 2025 09:59 ET (14:59 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"gpt_icon":0},{"id":"2500197418","title":"Wolfe Research Downgrades Immunovant to Peer Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2500197418","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500197418?lang=en_us&edition=fundamental","pubTime":"2025-01-03 20:26","pubTimestamp":1735907167,"startTime":"0","endTime":"0","summary":"Immunovant Inc (IMVT) has an average rating of buy and mean price target of $51.09, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMVT"],"gpt_icon":0},{"id":"2500019422","title":"Immunovant downgraded to Peer Perform from Outperform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2500019422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500019422?lang=en_us&edition=fundamental","pubTime":"2025-01-03 19:40","pubTimestamp":1735904441,"startTime":"0","endTime":"0","summary":"Wolfe Research analyst Andy Chen downgraded Immunovant (IMVT) to Peer Perform from Outperform. Published first on TheFly – the ultimate source for ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovant-downgraded-to-peer-perform-from-outperform-at-wolfe-research?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovant-downgraded-to-peer-perform-from-outperform-at-wolfe-research?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","IMVT","BK4588"],"gpt_icon":0},{"id":"2495521745","title":"We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2495521745","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495521745?lang=en_us&edition=fundamental","pubTime":"2024-12-30 23:17","pubTimestamp":1735571877,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.Given this risk, we thought we'd take a look at whether Immunovant  shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.Immunovant has a market capitalisation of US$3.6b and burnt through US$272m last year, which is 7.6% of the company's market value. Given that is a rather small percentage, it would probably be really easy for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/think-immunovant-nasdaq-imvt-afford-151757927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4588","NVIW.SI","SQQQ","IMVT","IE00B64PRP62.GBP","BK4112","NDAQ","MNQmain","TQQQ","IE00B3QW5Z07.USD","LU2210149790.SGD","USJW.SI","LU2095319765.USD","PSQ","IE00BKPKM429.USD","NQmain","TSYW.SI",".IXIC","BK4139","QID","USAW.SI","QLD","LU2210150020.SGD","IE00BGHQF748.EUR"],"gpt_icon":1},{"id":"2492410615","title":"Immunovant price target lowered to $45 from $47 at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2492410615","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492410615?lang=en_us&edition=fundamental","pubTime":"2024-12-20 20:20","pubTimestamp":1734697247,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Derek Archila lowered the firm’s price target on Immunovant  to $45 from $47 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma , aTyr Pharma , Rhythm Pharmaceuticals , and Xencor .Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks. 3 Best Stocks to Buy Now, 11/21/2024, According to Top Analysts. Immunovant’s Strategic Advances in Autoimmune Therapies. IMVT Earnings this Week: How Will it Perform?","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8UXduVDD554L.fL21Hrlzg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/1e5c62569304a546b8f4bd9cc2d706a2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8UXduVDD554L.fL21Hrlzg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/1e5c62569304a546b8f4bd9cc2d706a2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/immunovant-price-target-lowered-45-122047530.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunovant-price-target-lowered-45-122047530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMVT"],"gpt_icon":0},{"id":"2486523890","title":"Vertex leads J.P. Morgan's top biotech picks list for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2486523890","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486523890?lang=en_us&edition=fundamental","pubTime":"2024-11-26 04:10","pubTimestamp":1732565416,"startTime":"0","endTime":"0","summary":"DNY59 J.P. Morgan said its top biotech picks for 2025 were Vertex (NASDAQ:VRTX), Travere (NASDAQ:TVTX), SpringWorks (NASDAQ:SWTX), PTC Therapeutics (NASDAQ:PTCT), Wave Life Sciences (NASDAQ:WVE), Xeno","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/483098985/image_483098985.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/483098985/image_483098985.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4331812-vertex-leads-jp-morgans-top-biotech-picks-list-for-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IE00BZ9MQY76.HKD","LU1585245621.USD","LU0417517546.SGD","XENE","IMVT","IE0002270589.USD","PTCT","ROIV","IE00B19Z3B42.SGD","IE00B19Z9Z06.USD","IE00BFTCPJ56.SGD","LU2456880835.USD","TVTX","WVE","LU1093756168.USD","LU0079474960.USD","LU2237438978.USD","LU2362541513.USD","LU0053671581.USD","VRTX","LU2462157665.USD","LU1035775433.USD","LU0320765992.SGD","LU2362540622.SGD","LU0109394709.USD","IE00B4R5TH58.HKD","BK4533","BPMC","IE0002141913.USD","IE00B19Z3581.USD","LU1430594728.SGD","IE00BJT1NW94.SGD","IE0009355771.USD","LU0234570918.USD","IE00B894F039.SGD","BK4007","LU2362541273.HKD","IE00B19Z9P08.USD","BK4139","BK4585","LU0889565916.HKD","IE00B2B36J28.USD","LU0061475181.USD","SWTX","BK4539","LU0256863811.USD","EWTX","LU1069344957.HKD","LU1093756325.SGD","BK4567"],"gpt_icon":1},{"id":"2485420818","title":"Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024?","url":"https://stock-news.laohu8.com/highlight/detail?id=2485420818","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485420818?lang=en_us&edition=fundamental","pubTime":"2024-11-22 06:31","pubTimestamp":1732228300,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024.In this article, we are going to take a look at where Immunovant, Inc.  stands against the other biotech stocks.Biotechnology Stocks: Navigating Volatility Amid Market Fluctuations and Industry Growth. Contrary to Holz's perspective, 2024 has started off strongly for the biotechnology sector due to a rise in mergers and acquisitions as well as anticipations of falling interest rates. Therefore, estimates suggest that the worldwide biotechnology market might increase at a compound annual growth rate  of around 14% from 2024 to 2033, reaching an astonishing $5.7 trillion. The market for agricultural biotechnology is also expected to develop at a 7.9% compound annual growth rate  and reach $232 billion by 2032.“We still see tailwinds for the industry going forward. Smaller-cap names are still targets for acquisitions by bigger biopharma firms, and a wave of acquisitions has continued since late last year, partic","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZyvYqvKxNpBWlHwzdONqtQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/936769d778c202b5bc0f6633f10948f7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZyvYqvKxNpBWlHwzdONqtQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/936769d778c202b5bc0f6633f10948f7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-immunovant-inc-imvt-among-223140953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4159","MNQmain","PSQ","BK4585","TQQQ","QLD",".IXIC","IMVT","QID","CAGR","SQQQ","BK4139","NQmain","BK4588"],"gpt_icon":1},{"id":"2483021329","title":"Q2 2024 Roivant Sciences Ltd Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2483021329","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483021329?lang=en_us&edition=fundamental","pubTime":"2024-11-13 16:05","pubTimestamp":1731485156,"startTime":"0","endTime":"0","summary":"Stephanie Griffin; Vice President, Special Projects, Office of CEO; Roivant Sciences Ltd. Matthew Gline; Chief Executive Officer, Director; Roivant Sciences Ltd. Good day and thank you for standing by. Welcome to the Roivant second-quarter 2024 earnings conference call.  Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Stephanie Lee. Please go ahead.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q2-2024-roivant-sciences-ltd-080556159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMVT"],"gpt_icon":0},{"id":"2482484318","title":"Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2482484318","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482484318?lang=en_us&edition=fundamental","pubTime":"2024-11-08 23:38","pubTimestamp":1731080280,"startTime":"0","endTime":"0","summary":"Immunovant, Inc. IMVT reported second-quarter fiscal 2025 net loss of 74 cents per share, wider than the Zacks Consensus Estimate of a loss of 61 cents. The reported figure is also wider than the year-ago quarter's loss of 45 cents per share.Currently, Immunovant does not have any approved product in its portfolio. As a result, it has yet to generate revenues.See the ZacksEarnings Calendar to stay ahead of market-making news.Research and development (R&D) expenses totaled $97.3 million, up 103% from the year-ago quarter’s figure. The massive uptick can be attributed to activities in preparation for potential future clinical studies of IMVT-1402, including contract manufacturing costs for drug substance, higher overall clinical study costs related to batoclimab development programs and increased personnel-related expenses.IMVT may also transition its batoclimab CIDP study to a registrational CIDP program with IMVT-1402.The company believes that the data from the ongoing batoclimab CIDP ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunovants-q2-loss-wider-expected-153800243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","IE0009355771.USD","LU0170899867.USD","BK4187","IE00B4R5TH58.HKD","ALLO","BK4566","IE00BJT1NW94.SGD","IE00B19Z9Z06.USD","IE00B894F039.SGD","IE00B19Z9P08.USD","IE0031619046.USD","BK4123","IMVT","IE00B66KJ199.SGD","NVS","LU0211331839.USD","BK4139","LU0234570918.USD","IE00B2B36J28.USD","MG","LU0889565916.HKD","LU0320765992.SGD","BK4550","BK4516","BK4578","BIIB","BK4533","BK4588","IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK4505","LU0109394709.USD","BK4585","BK4007","IE00BFTCPJ56.SGD","GD","IE0002141913.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2481178333","title":"Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2481178333","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481178333?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:27","pubTimestamp":1731065220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 08, 2024 06:27 ET (11:27 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"gpt_icon":0},{"id":"2481189866","title":"Immunovant Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481189866","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481189866?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:42","pubTimestamp":1730990535,"startTime":"0","endTime":"0","summary":"Immunovant Inc reports results for the quarter ended in September 30 - Earnings Summary  Immunovant Inc IMVT.OQ reported a quarterly adjusted loss of 74 cents per share for the quarter ended September","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL8N3ME2F8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"gpt_icon":0},{"id":"2481375171","title":"Immunovant Fiscal Q2 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2481375171","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481375171?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:56","pubTimestamp":1730987783,"startTime":"0","endTime":"0","summary":"Immunovant  reported a fiscal Q2 net loss Thursday of $0.74 per diluted share, widening from a loss of $0.45 a year earlier.Analysts polled by Capital IQ expected a loss of $0.60.The clinical-stage immunology company didn't report any revenue for the quarter ended Sept. 30, as expected by analysts surveyed by Capital IQ.The company's shares were up more than 1% in recent premarket activity.Price: 29.10, Change: -0.29, Percent Change: -0.99","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","BK4139","IMVT"],"gpt_icon":0},{"id":"2481904146","title":"BRIEF-Immunovant Provides Development Updates And Reports Financial Results For The Quarter Ended September 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904146","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904146?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:13","pubTimestamp":1730985192,"startTime":"0","endTime":"0","summary":"BRIEF-Immunovant Provides Development Updates And Reports Financial Results For The Quarter Ended September 30, 2024Nov 7 (Reuters) - Immunovant Inc IMVT.O:IMMUNOVANT PROVIDES DEVELOPMENT UPDATES AND ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA65DHK9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","IMVT","BK4588"],"gpt_icon":0},{"id":"2481970212","title":"Immunovant Q2 2025 GAAP EPS $(0.74) Misses $(0.60) Estimate, Cash Balance Of $472.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2481970212","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481970212?lang=en_us&edition=fundamental","pubTime":"2024-11-07 19:58","pubTimestamp":1730980725,"startTime":"0","endTime":"0","summary":"Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.60) by 23.33 percent. This is a 64.44 percent decrease over losses of $(0.45) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41802200/immunovant-q2-2025-gaap-eps-0-74-misses-0-60-estimate-cash-balance-of-472-9m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immunovant Q2 2025 GAAP EPS $(0.74) Misses $(0.60) Estimate, Cash Balance Of $472.9M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"gpt_icon":0},{"id":"2481972334","title":"Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481972334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481972334?lang=en_us&edition=fundamental","pubTime":"2024-11-07 19:30","pubTimestamp":1730979001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA65DHK9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","IMVT","BK4139","BK4585"],"gpt_icon":0},{"id":"2481726972","title":"Immunovant: as of Sept 30, 2024, Immunovant's Cash and Cash Equivalents Totaled About $472.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2481726972","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481726972?lang=en_us&edition=fundamental","pubTime":"2024-11-07 19:30","pubTimestamp":1730979001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA65DHK9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","IMVT","BK4139"],"gpt_icon":0},{"id":"2481972390","title":"Immunovant Q2 Operating Expenses USD 115.743 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481972390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481972390?lang=en_us&edition=fundamental","pubTime":"2024-11-07 19:30","pubTimestamp":1730979000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nPLXBD595A:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMVT","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"2481972349","title":"Immunovant Q2 Basic EPS USD -0.74","url":"https://stock-news.laohu8.com/highlight/detail?id=2481972349","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481972349?lang=en_us&edition=fundamental","pubTime":"2024-11-07 19:30","pubTimestamp":1730979000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nPLXBD595A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","IMVT","BK4588"],"gpt_icon":0},{"id":"2481970542","title":"Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481970542","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481970542?lang=en_us&edition=fundamental","pubTime":"2024-11-07 19:30","pubTimestamp":1730979000,"startTime":"0","endTime":"0","summary":"Five Investigational New Drug  applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402. Proof of concept data from batoclimab trial in Graves’ disease  demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs ; initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year end. IND cleared for IMVT-1402 in rheumatoid arthritis , with potential best-in-class profile in difficult-to-treat  RA; initiation of potentially registrational trial to evaluate IMVT-1402 in D2T RA expected by March 31, 2025. On track to initiate potentially registrational trials with IMVT-1402 in four to five indications, inclusive of GD and D2T RA, by March 31, 2025. Immunovant to host development update call today, November 7, at 8 a.m. ET. “We are also excited to announce expansion of our IMVT-1402 development program into Rheumatology","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6EDLPKqoXNjuSfR3I70YPQ--~B/aD0zMjt3PTIwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/fca93fc54aa06d47cf61540482b0a710","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6EDLPKqoXNjuSfR3I70YPQ--~B/aD0zMjt3PTIwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/fca93fc54aa06d47cf61540482b0a710"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunovant-provides-development-updates-reports-113000731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","IE0031619046.USD","BK4123","BK4585","IE00B19Z4B17.USD","BK4550","IE00B7SZL793.SGD","LU0170899867.USD","MG","GD","BK4566","BK4139","BK4588","IE00B66KJ199.SGD","RA","BK4187","IMVT"],"gpt_icon":0},{"id":"2479147132","title":"Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2479147132","media":"THOMSON REUTERS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479147132?lang=en_us&edition=fundamental","pubTime":"2024-10-29 18:30","pubTimestamp":1730197800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nTUA2DN8MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMVT","BK4585","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunovant.com","stockEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":-0.1391},{"period":"3month","weight":-0.1792},{"period":"6month","weight":-0.1879},{"period":"1year","weight":-0.4298},{"period":"ytd","weight":-0.0052}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":-0.0316},{"period":"3month","weight":0.0199},{"period":"6month","weight":0.0578},{"period":"1year","weight":0.2403},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.07992},{"month":2,"riseRate":0,"avgChangeRate":-0.169332},{"month":3,"riseRate":0.2,"avgChangeRate":-0.041053},{"month":4,"riseRate":0.4,"avgChangeRate":-0.020694},{"month":5,"riseRate":0.4,"avgChangeRate":0.099229},{"month":6,"riseRate":0.2,"avgChangeRate":-0.098266},{"month":7,"riseRate":0.5,"avgChangeRate":0.046357},{"month":8,"riseRate":0.666667,"avgChangeRate":0.108139},{"month":9,"riseRate":0.833333,"avgChangeRate":0.124733},{"month":10,"riseRate":0.666667,"avgChangeRate":0.178851},{"month":11,"riseRate":0.666667,"avgChangeRate":0.072037},{"month":12,"riseRate":0.666667,"avgChangeRate":0.145522}],"exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunovant, Inc.,IMVT,Immunovant, Inc.股票,Immunovant, Inc.股票老虎,Immunovant, Inc.股票老虎国际,Immunovant, Inc.行情,Immunovant, Inc.股票行情,Immunovant, Inc.股价,Immunovant, Inc.股市,Immunovant, Inc.股票价格,Immunovant, Inc.股票交易,Immunovant, Inc.股票购买,Immunovant, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}